Investor Presentaiton
Advancing our complex therapeutics business
Products
MYRINGⓇ
Description
Contraceptive
vaginal ring (based
on etonogestrel/
EE/polymers)
Indication
Opportunity
Contraception
Circa $580m*
Original product:
NUVARINGⓇ from Merck
Status
Commercialized
ZORELINE®
Biodegradable SQ
implant
(goserelin)
Prostate & breast
cancer and benign
gynecological
indications
Circa $963m**
TIBELIAⓇ
Therapeutic solution
for HT composed of
tibolone (synthetic
steroid)
Menopause
*According to IQVIA, sales are for the 12 months ended June 2022
**Source: IQVIA quantitative market research, Q2 2022
Original product:
ZOLADEX® from
AstraZeneca
New formulations
assessed via
animal PK/PD
comparative study
for 1 month and 3
months implant
Commercialized
Circa $117m**
Original product:
LIVIALⓇ from Merck
Mithra Investor Presentation November 2023
28View entire presentation